Jupiter Life Line Hospitals Ltd
JLHL NSE
Jupiter Life Line Hospitals Ltd
Healthcare ServicesNSE: JLHL BSE: 543980 Hospitals
Key Fundamentals
MicrocapHospitalsHealthcare ServicesMarket Cap
₹10,314 Cr
Volatility
Moderate
P/E Ratio
55.63
EBITDA
₹386 Cr
Return on Equity
12.58%
Debt to Equity
0.38
Book Value
₹47.1
EPS
₹25.35
52W High
₹340
52W Low
₹235.6
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Jupiter Life Line Hospitals Ltd insights
43 extracted metrics + investor summaries across FY20–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
1- Company has delivered good profit growth of 143% CAGR over last 5 years
Growth Rate
Revenue Growth
15.89% ↗
Net Income Growth
0.21% ↗
Cash Flow Change
0.36% ↗
ROE
-11.97% ↗
ROCE
-11.00% ↗
EBITDA Margin (Avg.)
1.34% ↗
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 18d agoAI opinion · based on fundamentals
Risk high
Jupiter Life Line Hospitals Ltd is a western-India focused hospital chain with a market cap of ₹10,792 crore, trading at a PE of 56.1x. FY26 consolidated revenue grew 15.2% YoY to ₹1,500 crore with EBITDA of ₹343 crore (22.9% margin), while full-year PAT was essentially flat at ₹194 crore. The company is in an aggressive expansion phase, targeting 2,500 beds by FY28-29 from its current base.
Bull Case 8
- Strong 5-year profit CAGR of 143%, reflecting a significant earnings ramp-up from a low base as the hospital network matured
- FY26 revenue grew 15.2% YoY to ₹1,500 crore, demonstrating consistent top-line momentum even as new capacity ramps up
- ARPOB (Average Revenue Per Occupied Bed) grew 11.7% YoY to ₹67,700 in Q4 FY26, indicating improving case mix and pricing power
- Clear bed expansion visibility from ~1,060 operational beds to 2,500 beds by FY28-29 across MMR, Pune, and Indore — a potential doubling of capacity
- Dombivli greenfield hospital commissioned ahead of schedule and on budget, demonstrating execution capability on capital projects
- Company remains cash-positive and is funding growth through internal accruals with capped debt, reducing dilution risk
- 3-year compounded sales CAGR of 19% and 3-year profit CAGR of 37% show sustained growth trajectory beyond one-off gains
- Q4 FY26 quarterly revenue hit ₹388 crore (up 15.1% YoY) with Q4 PAT rising 12.7% to ₹50.6 crore, showing sequential improvement
Bear Case 8
- PE ratio of 56.1x is expensive relative to the healthcare sector median, leaving limited margin of safety if growth slows
- Stock trades at 7.06x book value, a steep premium that prices in significant future execution on expansion plans
- Full-year FY26 PAT was nearly flat at ₹194 crore vs ₹194 crore in FY25 (TTM profit growth of -1%), showing earnings stagnation despite revenue growth
- EBITDA margin dipped to 22.9% in FY26 from higher levels, pressured by new hospital ramp-up costs and rising employee expenses (up 11% YoY in Q3)
- Bed occupancy at 61.2% for the three established hospitals suggests room to fill before new capacity additions become earnings-accretive
- Expansion concentrated in western India (MMR, Pune, Indore) creates geographic concentration risk with limited diversification
- Higher depreciation and finance costs from expansion capex compressed Q1 FY26 PAT by 1.6% YoY even as EBITDA grew 19.6%, a trend likely to persist
- Dividend yield of just 0.3% offers negligible income return, making the stock entirely dependent on capital appreciation
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 16d ago Headwinds 1
- Net profit falls 14% in Q1 Aug 1
Net profit declined 14.4% to ₹375.12 million in Q1FY27 despite revenue growth, driven by rising operational and finance costs.
Positives 3
- Revenue surges 16.4% in Q1 Aug 1
Q1FY27 revenue grew 16.4% to ₹4,109.83 million, indicating strong top-line momentum and demand for hospital services.
- Sulcus acquisition completed Aug 1
Completed acquisition of Sulcus Private Limited for ₹3.78 crore, expanding the company's footprint.
- New CFO appointed Aug 1
Harshad Purani appointed as CFO, strengthening the leadership team.
Neutral 1
- 24th AGM held, resolutions approved Jul 17
Jupiter Life Line Hospitals held its 24th AGM on July 17, 2026, approving financial statements and key resolutions.
TL;DR: Jupiter Life Line Hospitals is growing revenue at a healthy 16.4% clip and actively expanding via acquisitions, but profitability is under pressure with net profit declining 14.4% due to rising operational and finance costs. The top-line trajectory is encouraging, though margin compression remains a near-term risk to monitor. If cost pressures ease or get absorbed through scale, earnings growth could re-accelerate in coming quarters.
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 243 | 263 | 273 | 291 | 289 | 335 | 333 | 337 | 353 | 394 | 365 | 388 | 411 |
| Expenses | 190 | 202 | 211 | 228 | 223 | 257 | 256 | 257 | 275 | 301 | 282 | 299 | 332 |
| Operating Profit | 53 | 61 | 62 | 63 | 65 | 78 | 76 | 80 | 78 | 92 | 83 | 89 | 79 |
| OPM % | 22% | 23% | 23% | 22% | 23% | 23% | 23% | 24% | 22% | 23% | 23% | 23% | 19% |
| Other Income | 4 | 3 | 8 | 10 | 7 | 7 | 7 | 7 | 13 | 11 | 3 | 11 | 11 |
| Interest | 12 | 12 | 1 | 1 | 1 | 1 | 3 | 6 | 8 | 8 | 8 | 9 | 13 |
| Depreciation | 11 | 11 | 11 | 10 | 11 | 14 | 14 | 18 | 21 | 21 | 22 | 23 | 26 |
| PBT | 34 | 41 | 58 | 62 | 60 | 70 | 67 | 63 | 62 | 74 | 57 | 68 | 51 |
| Tax % | -60% | 19% | 25% | 27% | 26% | 26% | 22% | 28% | 29% | 23% | 25% | 26% | 26% |
| Net Profit | 54 | 34 | 44 | 45 | 45 | 52 | 52 | 45 | 44 | 57 | 42 | 50 | 38 |
| EPS in Rs | 1.91 | 1.03 | 1.33 | 1.37 | 1.36 | 1.58 | 1.59 | 1.38 | 1.34 | 1.75 | 1.3 | 1.53 | 1.14 |
Profit & Loss
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 463 | 486 | 733 | 893 | 1,073 | 1,302 | 1,500 | 1,558 |
| Expenses | 379 | 419 | 580 | 691 | 831 | 999 | 1,156 | 1,214 |
| Operating Profit | 84 | 67 | 153 | 201 | 242 | 303 | 343 | 344 |
| OPM % | 18% | 14% | 21% | 23% | 23% | 23% | 23% | 22% |
| Other Income | 0 | 4 | 4 | 8 | 22 | 25 | 37 | 35 |
| Interest | 26 | 39 | 44 | 42 | 26 | 11 | 33 | 37 |
| Depreciation | 26 | 31 | 36 | 39 | 42 | 57 | 88 | 93 |
| PBT | 33 | 2 | 77 | 129 | 195 | 261 | 260 | 249 |
| Tax % | 10% | 248% | 34% | 43% | 10% | 26% | 25% | — |
| Net Profit | 30 | -2 | 51 | 73 | 177 | 194 | 194 | 188 |
| EPS in Rs | 1.17 | -0.09 | 2.01 | 2.58 | 5.39 | 5.89 | 5.92 | 5.72 |
| Div. Payout % | 0% | 0% | 0% | 0% | 4% | 3% | 3% | — |
Balance Sheet
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 51 | 51 | 51 | 57 | 66 | 66 | 66 |
| Reserves | 186 | 188 | 243 | 309 | 1,103 | 1,291 | 1,479 |
| Borrowings | 272 | 426 | 495 | 469 | 0 | 393 | 584 |
| Other Liabilities | 94 | 124 | 120 | 151 | 112 | 168 | 235 |
| Total Liabilities | 603 | 789 | 909 | 986 | 1,281 | 1,917 | 2,363 |
| Fixed Assets | 435 | 630 | 684 | 720 | 718 | 978 | 1,384 |
| CWIP | 10 | 26 | 27 | 29 | 74 | 185 | 129 |
| Investments | 2 | 7 | 3 | 2 | 17 | 507 | 486 |
| Other Assets | 156 | 126 | 195 | 235 | 473 | 247 | 364 |
| Total Assets | 603 | 789 | 909 | 986 | 1,281 | 1,917 | 2,363 |
Cash Flow
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Operating | 74 | 123 | 137 | 176 | 115 | 267 | 268 |
| Investing | -43 | -295 | -84 | -94 | -246 | -497 | -442 |
| Financing | -32 | 184 | 32 | -51 | 128 | 297 | 136 |
| Net Cash Flow | -1 | 12 | 85 | 31 | -3 | 66 | -38 |
| Free Cash Flow | 46 | -118 | 46 | 100 | 29 | -60 | -234 |
| CFO/OP | 106 | 198 | 95 | 97 | 68 | 109 | 97 |
Ratios
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 35 | 16 | 14 | 19 | 19 | 12 | 18 |
| Inventory Days | 64 | 48 | 39 | 44 | 41 | 38 | 49 |
| Days Payable | 268 | 217 | 157 | 164 | 120 | 99 | 121 |
| Cash Conversion Cycle | -169 | -152 | -104 | -101 | -59 | -49 | -54 |
| Working Capital Days | 17 | -7 | -24 | -24 | -5 | -19 | -21 |
| ROCE % | — | 7% | 17% | 21% | 22% | 18% | 15% |
Documents
1
Board Meeting Intimation for Pior Intimation Of The Board Meeting To Be Held On Friday, May 15, 2026
8h - Board meets May 15, 2026 to approve FY26 results, consider interim dividend and share split. 8h - Board meets May 15, 2026 to approve FY26 results, consider interim dividend and share split.
2
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
8h - Of Earnings Conference Call - Q4 & FY26 8h - Of Earnings Conference Call - Q4 & FY26
4
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
3 Apr - Submitted Regulation 74(5) certificate for quarter ended March 31, 2026; all holdings remain dematerialized. 3 Apr - Submitted Regulation 74(5) certificate for quarter ended March 31, 2026; all holdings remain dematerialized.
5
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
27 Mar - MMRDA allotted ~10,026.44 sqm BKC land on 80-year lease; one-time premium ~Rs.354 Crore; for ~400-bed hospital. 27 Mar - MMRDA allotted ~10,026.44 sqm BKC land on 80-year lease; one-time premium ~Rs.354 Crore; for ~400-bed hospital.
Frequently Asked Questions about Jupiter Life Line Hospitals Ltd
What does Jupiter Life Line Hospitals Ltd do?
Incorporated in 2007, Jupiter Life Line Hospitals Limited is a multi-specialty tertiary and quaternary healthcare provider in the Mumbai Metropolitan Area (MMR) and western region of India.[1]
Where is Jupiter Life Line Hospitals Ltd (JLHL) listed?
Jupiter Life Line Hospitals Ltd is listed on the Indian stock exchanges. It is listed on NSE: JLHL and BSE: 543980. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Jupiter Life Line Hospitals Ltd belong to?
Jupiter Life Line Hospitals Ltd operates in the Healthcare Services sector within the Hospitals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Jupiter Life Line Hospitals Ltd?
Jupiter Life Line Hospitals Ltd has a market capitalisation of approximately ₹10313.54 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Jupiter Life Line Hospitals Ltd?
The Price-to-Earnings (PE) ratio of Jupiter Life Line Hospitals Ltd is 55.63. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Jupiter Life Line Hospitals Ltd?
Over the past 52 weeks, Jupiter Life Line Hospitals Ltd has traded between a low of ₹235.6 and a high of ₹340. This range helps investors understand the stock's price volatility and recent trading levels.
Does Jupiter Life Line Hospitals Ltd pay dividends?
Yes, Jupiter Life Line Hospitals Ltd has a dividend yield of 0.32%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Jupiter Life Line Hospitals Ltd?
Jupiter Life Line Hospitals Ltd has a Return on Equity (ROE) of 12.58%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Jupiter Life Line Hospitals Ltd on Tapetide?
On Tapetide, you can view Jupiter Life Line Hospitals Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 2007, Jupiter Life Line Hospitals Limited is a multi-specialty tertiary and quaternary healthcare provider in the Mumbai Metropolitan Area (MMR) and western region of India.[1]